KEY TAKEWAYS ARIA is the primary safety concern associated with current anti-amyloid monoclonal antibody therapies for Alzheimer’s disease ARIA risk can be mitigated through careful patient selection, medication and blood … Read More

KEY TAKEWAYS Structured cognitive assessments are an important tool in the detection and diagnosis of early Alzheimer’s disease. Most older adults are aware of cognitive assessment screenings and most report … Read More

KEY TAKEWAYS The Alzheimer’s drug pipeline is rapidly evolving and gaining momentum with a growing, diverse set of 138+ drugs targeting multiple pathways. Key trends include real-world validation of anti-amyloid … Read More

KEY TAKEWAYS Blood biomarker tests have reached levels of accuracy on par with more intrusive diagnostic tests for Alzheimer’s disease such as cerebrospinal fluid analysis (CSF) and PET imaging. Blood … Read More

KEY TAKEWAYS Pre-clinical Alzheimer’s disease (PCAD) is a condition in which Alzheimer’s disease in the form of abnormal amyloid protein concentrations form in the brain before symptoms of Alzheimer’s disease … Read More

KEY TAKEWAYS Significant disparities persist in Alzheimer’s detection, diagnosis, treatment, and monitoring, disproportionately affecting racial/ethnic minorities, women, rural, low socioeconomic groups, and persons with Down Syndrome. Addressing disparities in healthcare … Read More